Authors
Latest:
Pharma’s Prescription for Social ROIMeasurement is a given in the pharmaceutical industry: dosage charts, chemistry formulas, budgets for testing, and budgets to go to market. When it comes to marketing, particularly through social media channels, measurement of return on investment (ROI) poses its own set of challenges.
Latest:
Pharmaceutical Executive's 2023 Emerging Pharma LeadersPharm Exec profiles its 2023 Emerging Pharma Leaders.
Latest:
Specialty Care Medicines: Managing the Impact of US Health ReformThere's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?
Latest:
Expanded Access: Get ReadyWhile the initiation and management of an access program can be challenging and requires careful assessment and planning, the benefits to patients, healthcare providers and sponsoring companies are immeasurable, writes Rob Fox. “Patients will find you.”In his keynote address at this year’s World Orphan Drug Congress, Henri Termeer, the former CEO, chairman and president of Genzyme reminded the audience that patients will actively seek out companies developing new therapeutics for their unmet medical needs.
Latest:
Tablet Innovation: Sizing up the ValueThe rising focus on difficulties in swallowing tablets spells a big opportunity for pharma.
Latest:
Bigger than Brand: Portfolio Positioning for PharmaJenna Earl outlines the three most important things to understand about portfolio positioning in pharma.
Latest:
The Path To Market Access: Winning Strategies To Build Value With PayersSuccess in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.
Latest:
Pushback on Rare Drug Prices: Not So Rare After AllRare Disease Day is a good moment to sound a warning that providers of rare medicines may be the next to land in the hot seat, writes Meg Alexander.
Latest:
The NHS Training Budget Requires More Than Just a Band-AidThe UK's National Health Services needs to rethink the ‘sticking plaster’ solution of training replacement staff, writes James Brook.
Latest:
Harnessing Digital to Construct New Business ModelsLife sciences companies must go beyond digitizing individual operations, and instead harness digital to design and construct entirely new business models, writes Brags Srinivasan.
Latest:
A New Era in Precision Gene EditingMedicine is entering a new era of “gene editing.” Instead of simply being able to “read” our genes, practitioners will be able to adapt and modify DNA sequencing in living cells to treat, cure, and even prevent disease. Defective genes responsible for life-threatening diseases can be rendered harmless by gene editing; it can also be used to develop new, precisely targeted biological drugs based on an individual’s distinct genetic markers. The full list of possibilities, in every area of the life sciences, is simply beyond imagination.
Latest:
A New Era in Precision Gene EditingMedicine is entering a new era of “gene editing.” Instead of simply being able to “read” our genes, practitioners will be able to adapt and modify DNA sequencing in living cells to treat, cure, and even prevent disease. Defective genes responsible for life-threatening diseases can be rendered harmless by gene editing; it can also be used to develop new, precisely targeted biological drugs based on an individual’s distinct genetic markers. The full list of possibilities, in every area of the life sciences, is simply beyond imagination.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
Think Globally, Act LocallyThe best approach to getting global brand campaigns to work all over the world
Latest:
Think Globally, Act LocallyThe best approach to getting global brand campaigns to work all over the world
Latest:
Market Access ReinventedThe key steps to implementing the "patient access" model of the future
Latest:
Market Access ReinventedThe key steps to implementing the "patient access" model of the future
Latest:
The 'Prosolidate' Push: New Agency Service MixThe advantages for brand teams in leveraging independent agencies in their campaigns.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
What Lessons Can the World Learn from Ebola?Ebola showed that when innovation is truly integrated, we can enter into unknown territories and bring new innovations with us, writes Neil Saward.
Latest:
The Importance of Risk Intelligence in the Supply ChainLeaders should understand the key themes of risk intelligence in the supply chain, writes Bronwyn Kunhardt.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
Latest:
Europe Under Pressure: Gearing Up for a Year of Regulatory ConvergenceIn the last year regulatory authorities sharpened their focus on gathering more data and on achieving transparency and harmonization. Erick Gaussens reviews 2015 and looks at companies’ need to respond to converging demands in 2016.
